复方苦参注射液联合新辅助化疗对宫颈癌临床效果及生存期的影响
|
摘要
目的:探讨复方苦参注射液联合新辅助化疗对宫颈癌的临床效果与生存期的影响。方法:宫颈癌患者152例,按照随机数字的方法分为对照组和观察组,每组76例,对照组患者采取新辅助化疗方案,观察组患者在新辅助化疗方案的基础上使用复方苦参注射液,对治疗的效果进行对比。结果:观察组患者的治疗效果优于对照组,数据差异具有统计学意义(z=6. 103,P <0. 05),在两组患者的各项不良反应情况中,只有白细胞下降的数据差异具有统计学意义(P <0. 05),观察组低于对照组,其余项目数据差异均不具有统计学意义(P> 0. 05),对照组患者的生存时间中位数为13. 325个月,观察组患者的生存时间中位数为16. 816个月,数据差异具有统计学意义(χ~2=4. 424,P <0. 05),对照组和观察组治疗前的CD_3~+,CD_4~+,CD_8~+,CD_4~+/CD_8~+,CD+16+56数据比较差异无统计学意义(t=0. 028,0. 496,0. 226,0. 000,0. 255,P> 0. 05)。治疗后,对照组的CD_3~+,CD_4~+,CD_4~+/CD_8~+,CD+16+56数据低于治疗前,数据差异具有统计学意义(t=2. 099,2. 221,45. 940,2. 083,P <0. 05),CD_8~+数据高于治疗前,数据差异具有统计学意义(t=3. 379,P <0. 05),观察组的CD_3~+,CD_4~+,CD_4~+/CD_8~+,CD+16+56数据高于治疗前,数据差异具有统计学意义(t=12. 095,6. 429,21. 761,6. 895,P <0. 05),CD_8~+数据低于治疗前,数据差异具有统计学意义(t=3. 053,P <0. 05)。结论:利用复方苦参注射液联合新辅助化疗对宫颈癌患者进行治疗,可以改善患者的治疗效果和免疫功能,稳定治疗过程中不良反应的发生,提高患者的生存质量和生存率,值得在临床工作中应用。
Objective:To investigate the clinical effect and survival time of Compound Kushen Injection and Neoadjuvant Chemotherapy in the treatment of cervical cancer. Methods: 152 patients with cervical cancer according to the random number method were divided into the control group and the observation group,76 cases in each group. The control group's patients were treated with neoadjuvant chemotherapy and the observation group's patients on the basis of neoadjuvant chemotherapy used Compound Kushen Injection. We compared the effect of treatment. Result: The treatment effect of the observation group was better than that of the control group,and the difference was statistically significant( z =6. 103,P < 0. 05). Among the two groups' adverse reactions,only the white blood cell decline data difference was statistically significant( P < 0. 05). The observation group's was lower than that of the control group and the remaining item data differences were not statistically significant( P > 0. 05). The median survival time of the control group was 13. 325 months,and the median survival time of the observation group was 16. 816 months,and the difference was statistically significant( χ~2= 4. 424,P < 0. 05). There was no significant difference in CD_3~+,CD_4~+,CD_8~+,CD_4~+/CD_8~+ and CD+16+56 before and after treatment in the control group and the observation group( t = 0. 028,0. 496,0. 226,0. 000,0. 255,P> 0. 05). After treatment,the control group's CD_3~+,CD_4~+,CD_4~+/CD_8~+ and CD+16+56 were lower than those before treat-ment,and the difference was statistically significant data( t = 2. 099,2. 221,45. 940,2. 083,P < 0. 05). CD_8~+ was higher than that before treatment,and the data had statistically significant difference( t = 3. 379,P < 0. 05). CD_3~+,CD_4~+,CD_4~+/CD_8~+ and CD+16+56 of the observation group were higher than those before treatment,and the difference was statistically significant( t = 12. 095,6. 429,21. 761,6. 895,P < 0. 05),and CD_8~+ was lower than that before treatment,and the difference was statistically significant( t = 3. 053,P < 0. 05). Conclusion: The use of Compound Kushen Injection combined with neoadjuvant chemotherapy in the treatment of cervical cancer patients can improve the patients' immune function,stabilize the adverse reactions,improve patients' quality of life and survival. It is worthy of clinical application.
Objective:To investigate the clinical effect and survival time of Compound Kushen Injection and Neoadjuvant Chemotherapy in the treatment of cervical cancer. Methods: 152 patients with cervical cancer according to the random number method were divided into the control group and the observation group,76 cases in each group. The control group's patients were treated with neoadjuvant chemotherapy and the observation group's patients on the basis of neoadjuvant chemotherapy used Compound Kushen Injection. We compared the effect of treatment. Result: The treatment effect of the observation group was better than that of the control group,and the difference was statistically significant( z =6. 103,P < 0. 05). Among the two groups' adverse reactions,only the white blood cell decline data difference was statistically significant( P < 0. 05). The observation group's was lower than that of the control group and the remaining item data differences were not statistically significant( P > 0. 05). The median survival time of the control group was 13. 325 months,and the median survival time of the observation group was 16. 816 months,and the difference was statistically significant( χ~2= 4. 424,P < 0. 05). There was no significant difference in CD_3~+,CD_4~+,CD_8~+,CD_4~+/CD_8~+ and CD+16+56 before and after treatment in the control group and the observation group( t = 0. 028,0. 496,0. 226,0. 000,0. 255,P> 0. 05). After treatment,the control group's CD_3~+,CD_4~+,CD_4~+/CD_8~+ and CD+16+56 were lower than those before treat-ment,and the difference was statistically significant data( t = 2. 099,2. 221,45. 940,2. 083,P < 0. 05). CD_8~+ was higher than that before treatment,and the data had statistically significant difference( t = 3. 379,P < 0. 05). CD_3~+,CD_4~+,CD_4~+/CD_8~+ and CD+16+56 of the observation group were higher than those before treatment,and the difference was statistically significant( t = 12. 095,6. 429,21. 761,6. 895,P < 0. 05),and CD_8~+ was lower than that before treatment,and the difference was statistically significant( t = 3. 053,P < 0. 05). Conclusion: The use of Compound Kushen Injection combined with neoadjuvant chemotherapy in the treatment of cervical cancer patients can improve the patients' immune function,stabilize the adverse reactions,improve patients' quality of life and survival. It is worthy of clinical application.
引文
[1]包鹤龄,刘韫宁,王黎君,等.中国2006—2012年子宫颈癌死亡情况与变化趋势分析[J].中华流行病学杂志,2017,38(1):58-64.
[2]袁秀英,刘燕燕,刘小媚,等.紫杉醇、卡铂化疗联合放疗在中晚期宫颈癌患者中的效果[J].广东医学,2017,38(z1):242
[3]胡艳,郭亚焕,付玉兰,等.宫颈癌保留盆腔神经的广泛子宫切除术的疗效分析[J].现代肿瘤医学,2017,25(10):1601-1604.
[4]王新会,陈欢欢,李娟,等.伊立替康联合顺铂新辅助化疗对宫颈癌患者血清CD105、OPN、SCCAg、CEA及免疫T细胞亚群的影响[J].海南医学院学报,2017,23(6):797-800.
[5]王玲,张建果,陈兵,等.黄芪联合丹参注射液促进异环磷酰胺治疗老年宫颈癌患者增效减毒的机制[J].中国老年学杂志,2017,37(5):1162-1164.
[6]程琪辉,陈赟,孙丽萍,等.宫颈癌介入治疗的临床意义[J].浙江临床医学,2017,19(4):714-715.
[7]赵瑜,李赟.替吉奥联合奥沙利铂方案在局部进展期胃癌新辅助化疗中的疗效观察[J].中国基层医药,2017,24(9):1316-1320.
[8]王琳,李洪伟,施裕新,等.高效抗逆转录病毒治疗联合化疗对HIV感染合并肺癌患者的CD+4计数和生存质量评分的影响[J].临床肺科杂志,2017,22(2):220-223.
[9]宋鑫,王爱民,贾树杰,等.人宫颈癌基因在结直肠癌和结直肠腺瘤组织的表达及其意义[J].中华实验外科杂志,2017,34(1):55-57.
[10]何友梅,吴小芬,陶国芝,等.宫颈上皮内瘤变患病危险因素分析[J].预防医学,2017,29(5):524-526.
[11]薛剑侠,王玉兰,李晓旭,等.人乳头瘤病毒在宫颈癌发病机制中的研究进展[J].中国药物与临床,2017,17(4):542-543.
[12]陈春琴,邬素芳.高危型人类乳头瘤病毒E7促进宫颈癌变的分子机制研究进展[J].浙江临床医学,2017,19(4):770-772.
[13]覃业语,韦知樱,韩方璇,等.扶正固本汤联合化疗治疗宫颈癌临床疗效及安全性分析[J].广州中医药大学学报,2016,33(3):321-324.
[14]孙茂春,康晓琳. HPV-DNA联合TCT检查对于诊断宫颈疾病的价值及其病理分型研究[J].中国妇幼健康研究,2016,27(5):647-649.
[15]文露,李飞平,周彦杰,等. 3. 0T磁共振弥散加权成像在鉴别早期宫颈癌小转移性淋巴结与非转移性淋巴结价值的初步探讨[J].中国医学计算机成像杂志,2015,21(4):354-357.
[16]郑迎春,李真,陈菁,等.不同的新辅助化疗方法对宫颈癌患者治疗效果及生存期的影响[J].安徽医药,2016,20(10):1922-1925.
[17]Zhao Y,Shen L,Chen X,et al. High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer[J]. Histol Histopathol,2015,30(11):1313-1320.
[18]李雷蕾,王文玲,董洪敏,等.局部进展期直肠癌术前同步放化疗后联合新辅助化疗的前瞻性Ⅱ期随机对照研究[J].中华放射医学与防护杂志,2017,37(2):107-113.
[19]Sood S,Patel FD,Ghosh S,et al. Epigenetic alteration by DNA methylation of ESR1,MYOD1 and hTERT gene promoters is useful for prediction of response in patients of locally advanced invasive cervical carcinoma treated by chemoradiation[J]. Clin Oncol(RColl Radiol),2015,27(12):720-727.
[20]文军.生血宝合剂对肿瘤气血两虚证化疗毒副反应的临床研究[J].中国医药导刊,2017,19(2):153-154,172.
[2]袁秀英,刘燕燕,刘小媚,等.紫杉醇、卡铂化疗联合放疗在中晚期宫颈癌患者中的效果[J].广东医学,2017,38(z1):242
[3]胡艳,郭亚焕,付玉兰,等.宫颈癌保留盆腔神经的广泛子宫切除术的疗效分析[J].现代肿瘤医学,2017,25(10):1601-1604.
[4]王新会,陈欢欢,李娟,等.伊立替康联合顺铂新辅助化疗对宫颈癌患者血清CD105、OPN、SCCAg、CEA及免疫T细胞亚群的影响[J].海南医学院学报,2017,23(6):797-800.
[5]王玲,张建果,陈兵,等.黄芪联合丹参注射液促进异环磷酰胺治疗老年宫颈癌患者增效减毒的机制[J].中国老年学杂志,2017,37(5):1162-1164.
[6]程琪辉,陈赟,孙丽萍,等.宫颈癌介入治疗的临床意义[J].浙江临床医学,2017,19(4):714-715.
[7]赵瑜,李赟.替吉奥联合奥沙利铂方案在局部进展期胃癌新辅助化疗中的疗效观察[J].中国基层医药,2017,24(9):1316-1320.
[8]王琳,李洪伟,施裕新,等.高效抗逆转录病毒治疗联合化疗对HIV感染合并肺癌患者的CD+4计数和生存质量评分的影响[J].临床肺科杂志,2017,22(2):220-223.
[9]宋鑫,王爱民,贾树杰,等.人宫颈癌基因在结直肠癌和结直肠腺瘤组织的表达及其意义[J].中华实验外科杂志,2017,34(1):55-57.
[10]何友梅,吴小芬,陶国芝,等.宫颈上皮内瘤变患病危险因素分析[J].预防医学,2017,29(5):524-526.
[11]薛剑侠,王玉兰,李晓旭,等.人乳头瘤病毒在宫颈癌发病机制中的研究进展[J].中国药物与临床,2017,17(4):542-543.
[12]陈春琴,邬素芳.高危型人类乳头瘤病毒E7促进宫颈癌变的分子机制研究进展[J].浙江临床医学,2017,19(4):770-772.
[13]覃业语,韦知樱,韩方璇,等.扶正固本汤联合化疗治疗宫颈癌临床疗效及安全性分析[J].广州中医药大学学报,2016,33(3):321-324.
[14]孙茂春,康晓琳. HPV-DNA联合TCT检查对于诊断宫颈疾病的价值及其病理分型研究[J].中国妇幼健康研究,2016,27(5):647-649.
[15]文露,李飞平,周彦杰,等. 3. 0T磁共振弥散加权成像在鉴别早期宫颈癌小转移性淋巴结与非转移性淋巴结价值的初步探讨[J].中国医学计算机成像杂志,2015,21(4):354-357.
[16]郑迎春,李真,陈菁,等.不同的新辅助化疗方法对宫颈癌患者治疗效果及生存期的影响[J].安徽医药,2016,20(10):1922-1925.
[17]Zhao Y,Shen L,Chen X,et al. High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer[J]. Histol Histopathol,2015,30(11):1313-1320.
[18]李雷蕾,王文玲,董洪敏,等.局部进展期直肠癌术前同步放化疗后联合新辅助化疗的前瞻性Ⅱ期随机对照研究[J].中华放射医学与防护杂志,2017,37(2):107-113.
[19]Sood S,Patel FD,Ghosh S,et al. Epigenetic alteration by DNA methylation of ESR1,MYOD1 and hTERT gene promoters is useful for prediction of response in patients of locally advanced invasive cervical carcinoma treated by chemoradiation[J]. Clin Oncol(RColl Radiol),2015,27(12):720-727.
[20]文军.生血宝合剂对肿瘤气血两虚证化疗毒副反应的临床研究[J].中国医药导刊,2017,19(2):153-154,172.